Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Saied Hafizi-Lotfabadi"'
Autor:
Daryoush Hamidi-Alamdari, Amin Ghiabi, Mahnaz Amini, George Koliakos, Seyed M. Tavousi, Abass Ali-Zeraati, Ahmad Bagheri-Moghaddam, Mahnaz Mozdourian, Ashraf Tavanaee-Sani, Hossin Safari, Shohreh Vojouhi, Fatemeh Barazandeh-Ahmadabadi, Marzieh Agheli-Rad, Saied Hafizi-Lotfabadi, Shahram Amini, Arash Peivandi-Yazdi, Farid Poursadegh, Alireza Sedaghat, Zahra Javidarabshahi, Negar Morovatdar, Shima Nabavi-Mahalli, Omid Rajabi, Seyed Majid-Hosseini
Publikováno v:
Revista de investigaci�n Cl�nica. 73
Background: There is no pharmacological intervention on the treatment of hypoxemia and respiratory distress in COVID-19 patients. Objective: The objective of the study was to study the effect of the reduced form of methylene blue (MB) on the improvem
Autor:
Daryoush Hamidi Alamdari, Saied Hafizi Lotfabadi, Behzad Mavaji Darban, Marzieh Agheli-Rad, Shahin Saadatian, Seyed Hadi Hashemi, Fatemeh Barazandeh Ahmadabadi, Negar Morovatdar, Mohammad Arastoo, Bharat Bhushan
Publikováno v:
University of Aberdeen-PURE
Background: Methylene blue (MB) possesses all the required properties for the clinical management of COVID-19. We have coined methylene blue as an anti-hypoxemia and anti-respiratory distress agent and previously witnessed promising results in phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95b1656466b6f8c03146bcdf11b1bee8
https://abdn.pure.elsevier.com/en/en/researchoutput/methylene-blue-for-treatment-of-hospitalized-covid19-patients-randomized-controlled-openlabel-clinical-trial-phase-3(61565c11-e3b0-4e62-8cbd-80d484f723ba).html
https://abdn.pure.elsevier.com/en/en/researchoutput/methylene-blue-for-treatment-of-hospitalized-covid19-patients-randomized-controlled-openlabel-clinical-trial-phase-3(61565c11-e3b0-4e62-8cbd-80d484f723ba).html
Publikováno v:
Clinical & Translational Investigation / Revista de Investigación Clínica; Sep/Oct2021, Vol. 73 Issue 5, p288-296, 9p